Zobrazeno 1 - 4
of 4
pro vyhledávání: '"de Paor, Muirrean"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Li, Xiao, Bilcke, Joke, van der Velden, Alike W., Bruyndonckx, Robin, Coenen, Samuel, Bongard, Emily, de Paor, Muirrean, Chlabicz, Slawomir, Godycki-Cwirko, Maciek, Francis, Nick, Aabenhus, Rune, Bucher, Heiner C., Colliers, Annelies, De Sutter, An, Garcia-Sangenis, Ana, Glinz, Dominik, Harbin, Nicolay J., Kosiek, Katarzyna, Lindbaek, Morten, Lionis, Christos, Llor, Carl, Miko-Pauer, Reka, Jurgute, Ruta Radzeviciene, Seifert, Bohumil, Sundvall, Par-Daniel, Lundgren, Pia Touboul, Tsakountakis, Nikolaos, Verheij, Theo J., Goossens, Herman, Butler, Christopher C., Beutels, Philippe
Publikováno v:
Li, X, Bilcke, J, van der Velden, A W, Bruyndonckx, R, Coenen, S, Bongard, E, de Paor, M, Chlabicz, S, Godycki-Cwirko, M, Francis, N, Aabenhus, R, Bucher, H C, Colliers, A, De Sutter, A, Garcia-Sangenis, A, Glinz, D, Harbin, N J, Kosiek, K, Lindbaek, M, Lionis, C, Llor, C, Miko-Pauer, R, Jurgute, R R, Seifert, B, Sundvall, P-D, Lundgren, P T, Tsakountakis, N, Verheij, T J, Goossens, H, Butler, C C, Beutels, P & ALIC4Etrial Investigators 2023, ' Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness : economic evaluation alongside the randomised controlled ALIC 4 E trial in 15 European countries ', European Journal of Health Economics, vol. 24 . https://doi.org/10.1007/s10198-022-01521-2
The European journal of health economics
The European journal of health economics
Background Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::104f236a281a51dd4ef4bca7faca5e38
https://curis.ku.dk/portal/da/publications/costeffectiveness-of-adding-oseltamivir-to-primary-care-for-influenzalikeillness(9635d196-2ad2-4c38-8dae-6cdc3f07e7b4).html
https://curis.ku.dk/portal/da/publications/costeffectiveness-of-adding-oseltamivir-to-primary-care-for-influenzalikeillness(9635d196-2ad2-4c38-8dae-6cdc3f07e7b4).html
Autor:
Li, Xiao, Bilcke, Joke, van der Velden, Alike W., Bruyndonckx, Robin, Coenen, Samuel, Bongard, Emily, de Paor, Muirrean, Chlabicz, Slawomir, Godycki-Cwirko, Maciek, Francis, Nick, Aabenhus, Rune, Bucher, Heiner C., Colliers, Annelies, De Sutter, An, Garcia-Sangenis, Ana, Glinz, Dominik, Harbin, Nicolay J., Kosiek, Katarzyna, Lindbæk, Morten, Lionis, Christos
Publikováno v:
European Journal of Health Economics; Aug2023, Vol. 24 Issue 6, p909-922, 14p
Autor:
Li, Xiao, Bilcke, Joke, van der Velden, Alike W., Bruyndonckx, Robin, Coenen, Samuel, Bongard, Emily, de Paor, Muirrean, Chlabicz, Slawomir, Godycki-Cwirko, Maciek, Francis, Nick, Aabenhus, Rune, Bucher, Heiner C., Colliers, Annelies, De Sutter, An, Garcia-Sangenis, Ana, Glinz, Dominik, Harbin, Nicolay Jonassen, Kosiek, Katarzyna, Lindbæk, Morten, Lionis, Christos, Llor, Carl, Mikó-Pauer, Réka, Radzeviciene Jurgute, Ruta, Seifert, Bohumil, Sundvall, Pär-Daniel, Touboul Lundgren, Pia, Tsakountakis, Nikolaos, Verheij, Theo J., Goossens, Herman, Butler, Christopher C., Beutels, Philippe
Publikováno v:
Li, Xiao Bilcke, Joke van der Velden, Alike W. Bruyndonckx, Robin Coenen, Samuel Bongard, Emily de Paor, Muirrean Chlabicz, Slawomir Godycki-Cwirko, Maciek Francis, Nick Aabenhus, Rune Bucher, Heiner C. Colliers, Annelies De Sutter, An Garcia-Sangenis, Ana Glinz, Dominik Harbin, Nicolay Jonassen Kosiek, Katarzyna Lindbæk, Morten Lionis, Christos Llor, Carl Mikó-Pauer, Réka Radzeviciene Jurgute, Ruta Seifert, Bohumil Sundvall, Pär-Daniel Touboul Lundgren, Pia Tsakountakis, Nikolaos Verheij, Theo J. Goossens, Herman Butler, Christopher C. Beutels, Philippe . Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries. European Jo
European Jo
European Jo
Externí odkaz:
http://hdl.handle.net/10852/100130